상세 보기
Effectiveness and Safety of Bictegravir/ Emtricitabine/Tenofovir Alafenamide in People with HIV in Korea: 24-Month Data from BICSTaR
- Kim, Yeon-Sook;
- Choi, Jun Yong;
- Park, Dae Won;
- Kim, Shin-Woo;
- Kim, Tae Hyong;
- 외 5명
WEB OF SCIENCE
0SCOPUS
0초록
BICtegravir Single Tablet Regimen is a multi-national observational cohort study evaluating the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with human immunodeficiency virus. We present 24-month data from participants in Korea. Eighty-eight participants (36 treatment-naive [TN], 52 treatment-experienced [TE]) were included. At 24 months, 100% (29/29) of TN and 100% (37/37) of TE participants had HIV-1 RNA <50 copies/mL (missing=excluded analysis). BIC/FTC/TAF persistence was 100% (33/33) and 96.1% (49/51) in TN and TE participants, respectively. Drug-related adverse events occurred in 2 TN participants. Improvements in some patient-reported outcomes were observed. BIC/FTC/TAF maintained effectiveness,
키워드
- 제목
- Effectiveness and Safety of Bictegravir/ Emtricitabine/Tenofovir Alafenamide in People with HIV in Korea: 24-Month Data from BICSTaR
- 저자
- Kim, Yeon-Sook; Choi, Jun Yong; Park, Dae Won; Kim, Shin-Woo; Kim, Tae Hyong; Ryu, Julie; Harrison, Rebecca; Lee, Jeong-a; Park, Flora; Lee, Sun Hee
- 발행일
- 2025-09
- 유형
- Article
- 권
- 57
- 호
- 3
- 페이지
- 424 ~ 430